ALK-Abelló Logo

ALK-Abelló

Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.

ALK | CO

Overview

Corporate Details

ISIN(s):
DK0061802139
LEI:
529900SGCREUZCZ7P020
Country:
Denmark
Address:
Bøge Alle 6-8, 2970 Hørsholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ALK-Abelló is a global pharmaceutical company specializing in the research, development, and manufacturing of allergy immunotherapy (AIT) products. A pioneer in the field for over a century, the company focuses on creating treatments that address the underlying cause of allergies, rather than merely managing symptoms. Its portfolio encompasses a range of evidence-based AIT products, including tablets, drops, and injections, as well as emergency treatments for severe allergic reactions like anaphylaxis. ALK's primary therapeutic areas are respiratory allergies, food allergies, and anaphylaxis. The company is committed to scientific innovation and expanding access to its solutions, such as needle-free adrenaline treatments, to improve the lives of people with allergies worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 17:17
Regulatory News Service
Danish 102.5 KB
2025-11-12 17:17
Earnings Release
Danish 3.3 KB
2025-11-12 17:17
Regulatory News Service
English 104.1 KB
2025-11-12 17:17
Earnings Release
English 2.8 KB
2025-09-17 09:44
M&A Activity
Danish 174.5 KB
2025-09-17 09:44
M&A Activity
Danish 10.0 KB
2025-09-17 09:44
M&A Activity
English 8.9 KB
2025-09-17 09:44
M&A Activity
English 274.6 KB
2025-08-21 07:30
Earnings Release
English 11.5 KB
2025-08-21 07:30
Interim Report
English 505.8 KB
2025-08-21 07:30
Interim Report
English 505.8 KB
2025-08-21 07:30
Earnings Release
English 12.0 KB
2025-08-12 14:45
Earnings Release
Danish 103.0 KB
2025-08-12 14:45
Earnings Release
Danish 3.7 KB
2025-08-12 14:45
Earnings Release
English 108.6 KB

Automate Your Workflow. Get a real-time feed of all ALK-Abelló filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALK-Abelló

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ALK-Abelló via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

D&D Pharmatech Inc. Logo
Develops oral & injectable peptide therapies for metabolic & chronic diseases like obesity.
South Korea
347850
Dechra Pharmaceuticals PLC Logo
Develops & sells veterinary pharmaceuticals for companion animals, exclusively to veterinarians.
United Kingdom
DPH
Denali Therapeutics Inc. Logo
Developing therapies for neurodegenerative diseases that cross the blood-brain barrier.
United States of America
DNLI
Dermapharm Holding SE Logo
Manufactures patent-free branded pharmaceuticals & healthcare products for niche markets.
Germany
DMP
Dermata Therapeutics, Inc. Logo
Develops OTC skin treatments using a unique delivery technology from freshwater sponges.
United States of America
DRMA
Design Therapeutics, Inc. Logo
Develops small molecule genomic medicines to treat serious genetic diseases by modulating genes.
United States of America
DSGN
Deutsche Biotech Innovativ AG Logo
Develops biomarker-driven therapeutics and diagnostics for serious diseases with unmet needs.
Germany
DBI
DEVA HOLDİNG A.Ş. Logo
Global manufacturer of human/veterinary pharmaceuticals, APIs, and medical ampoules.
Spain
DEVA
Devyser Diagnostics Logo
Develops & sells genetic DNA test kits for labs in oncology, transplant & reproductive health.
Sweden
DVYSR
DiaMedica Therapeutics Inc. Logo
Developing a novel protein therapy for acute ischemic stroke and preeclampsia.
United States of America
DMAC

Talk to a Data Expert

Have a question? We'll get back to you promptly.